Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year 2020 Concept
Fiscal Year 2021 Concept
For the published program announcements with special receipt, referral, or review considerations, see the August 16, 2019 Guide announcements:
- Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)
- Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinical Trial Not Allowed)
Request for Applications—proposed FY 2021 initiative
Contact: Leighton Thomas
Objective: To enhance understanding of the underlying mechanisms of the induction, maintenance, and loss of immune tolerance in humans, and to develop improved tolerogenic interventions for preventing and treating immune system-mediated diseases (including transplant rejection, autoimmune diseases, and asthma and allergic diseases).
Description: This initiative will renew NIAID's successful Immune Tolerance Network (ITN), a consortium of basic and clinical scientists that 1) develops a scientific agenda for clinical trials and mechanistic studies of various approaches to tolerance induction, 2) designs and conducts clinical trials at all phases to determine the feasibility, safety, toxicity, and efficacy of tolerogenic intervention strategies for multiple immune system diseases, 3) designs and conducts research to delineate the underlying mechanisms of immune tolerance in conjunction with clinical trials undertaken by the ITN as well as research projects sponsored by other federal and private sector organizations and companies, and 4) develops, tests, and validates assays to measure the induction, maintenance, and loss of immune tolerance in humans. For this initiative, tolerance is broadly defined as a clinical phenotype characterized by selective elimination of pathogenic immune responses to relevant antigens (e.g., alloantigens, autoantigens, or allergens) with preservation of protective immunity, with no or minimal ongoing immunologic intervention. Approaches may target antigen-specific receptors, molecules of the co-stimulation pathways, homing molecules, or other relevant approaches, and may use any of a variety of agents including antigen, peptides, altered peptides, monoclonal antibody blockade, cytokines, cellular therapies, molecularly engineered cells or tissues, DNA vectors, or other relevant molecules.